12.43
+0.97(+8.46%)
Currency In USD
| Previous Close | 11.46 |
| Open | 11.48 |
| Day High | 12.99 |
| Day Low | 11.41 |
| 52-Week High | 13.85 |
| 52-Week Low | 5.79 |
| Volume | 5.76M |
| Average Volume | 2.78M |
| Market Cap | 2.16B |
| PE | -8.69 |
| EPS | -1.43 |
| Moving Average 50 Days | 11.64 |
| Moving Average 200 Days | 9.93 |
| Change | 0.97 |
If you invested $1000 in Ocular Therapeutix, Inc. (OCUL) 10 years ago, it would be worth $1,376.52 as of December 04, 2025 at a share price of $12.43. Whereas If you bought $1000 worth of Ocular Therapeutix, Inc. (OCUL) shares 5 years ago, it would be worth $611.11 as of December 04, 2025 at a share price of $12.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR
GlobeNewswire Inc.
Nov 24, 2025 12:00 PM GMT
First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, complementary superiority trials using a novel ord
Ocular Therapeutix™ to Participate in November and December Investor Conferences
GlobeNewswire Inc.
Nov 12, 2025 12:00 PM GMT
BEDFORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor c
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
GlobeNewswire Inc.
Nov 04, 2025 12:00 PM GMT
SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission for AXPAXLI in wet AMD BEDFORD, M